Gene-Based Blood Test for Melanoma Spread Evaluates Treatment Progress

Source: NYU Langone Health, February 2021

A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in the late stages of one of the most aggressive forms of skin cancer, a new study finds.

Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, the investigation looked at adults with undetectable levels of freely circulating tumor DNA (ctDNA) four weeks into drug treatment for metastatic melanoma tumors that cannot be removed surgically or are unresectable.